JP2025520232A5 - - Google Patents

Info

Publication number
JP2025520232A5
JP2025520232A5 JP2023547426A JP2023547426A JP2025520232A5 JP 2025520232 A5 JP2025520232 A5 JP 2025520232A5 JP 2023547426 A JP2023547426 A JP 2023547426A JP 2023547426 A JP2023547426 A JP 2023547426A JP 2025520232 A5 JP2025520232 A5 JP 2025520232A5
Authority
JP
Japan
Prior art keywords
seq
amino acid
cancer
acid sequence
variable region
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2023547426A
Other languages
English (en)
Japanese (ja)
Other versions
JP2025520232A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/CN2023/087998 external-priority patent/WO2023246247A1/zh
Publication of JP2025520232A publication Critical patent/JP2025520232A/ja
Publication of JP2025520232A5 publication Critical patent/JP2025520232A5/ja
Pending legal-status Critical Current

Links

JP2023547426A 2022-06-22 2023-04-13 医薬組成物及びその使用 Pending JP2025520232A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CN202210712836.9 2022-06-22
CN202210712836 2022-06-22
PCT/CN2023/087998 WO2023246247A1 (zh) 2022-06-22 2023-04-13 药物组合物及其用途

Publications (2)

Publication Number Publication Date
JP2025520232A JP2025520232A (ja) 2025-07-03
JP2025520232A5 true JP2025520232A5 (enExample) 2026-04-15

Family

ID=89218472

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2023547426A Pending JP2025520232A (ja) 2022-06-22 2023-04-13 医薬組成物及びその使用

Country Status (10)

Country Link
US (1) US20250129163A1 (enExample)
EP (1) EP4321537A4 (enExample)
JP (1) JP2025520232A (enExample)
KR (1) KR20250026284A (enExample)
CN (1) CN117257934A (enExample)
AU (1) AU2023287932A1 (enExample)
CA (1) CA3208473A1 (enExample)
IL (1) IL317556A (enExample)
MX (1) MX2024015303A (enExample)
WO (1) WO2023246247A1 (enExample)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR112022002028A2 (pt) * 2019-08-02 2022-04-12 Cttq Akeso Shanghai Biomed Tech Co Ltd Anticorpo anti-pd-1 e uso farmacêutico do mesmo
KR20250112917A (ko) 2022-12-12 2025-07-24 라노바 메디신즈 리미티드 Pd1 및 vegf를 표적으로 하는 이중특이적 항체
WO2025201450A1 (zh) * 2024-03-27 2025-10-02 康方汇科(上海)生物有限公司 药物组合及用途

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US5747654A (en) 1993-06-14 1998-05-05 The United States Of America As Represented By The Department Of Health And Human Services Recombinant disulfide-stabilized polypeptide fragments having binding specificity
US7923538B2 (en) * 2005-07-22 2011-04-12 Kyowa Hakko Kirin Co., Ltd Recombinant antibody composition
EP3328418A1 (en) * 2015-07-29 2018-06-06 Novartis AG Combination therapies comprising antibody molecules to pd-1
US11827697B2 (en) * 2018-02-11 2023-11-28 Beijing Hanmi Pharmaceutical Co., Ltd. Anti-PD-1/anti-VEGF natural antibody structure like heterodimeric form bispecific antibody and preparation thereof
CN119431579A (zh) * 2018-03-09 2025-02-14 艾吉纳斯公司 抗cd73抗体及其使用方法
CN109053895B (zh) * 2018-08-30 2020-06-09 中山康方生物医药有限公司 抗pd-1-抗vegfa的双功能抗体、其药物组合物及其用途
CN110498857B (zh) * 2019-08-09 2022-09-09 安徽瀚海博兴生物技术有限公司 一种抗vegf-抗pd1双特异性抗体
MX2022006330A (es) * 2019-11-25 2022-08-17 Akeso Biopharma Inc Anticuerpo biespecífico anti-pd-1 anti-vegfa, composición farmacéutica y uso del mismo.
CN110960543A (zh) * 2019-12-10 2020-04-07 安徽瀚海博兴生物技术有限公司 一种联合抗vegf-抗pd1双特异性抗体用于制备抗癌药物
TWI813934B (zh) * 2020-01-21 2023-09-01 大陸商甫康(上海)健康科技有限責任公司 一種雙特異性抗pd-l1/vegf抗體及其用途
BR112022021426A2 (pt) * 2020-04-22 2022-12-13 Akeso Biopharma Inc Anticorpo biespecífico anti-cd73/anti-pd-1, molécula de ácido nucleico isolada, vetor, célula hospedeira, método para preparar o anticorpo biespecífico anti-cd73/anti-pd-1, conjugado, kit, usos do anticorpo biespecífico anti-cd73/anti-pd-1, composição farmacêutica, método in vitro, linhagem celular de hibridoma e anticorpo monoclonal anti-cd73
WO2021213466A1 (zh) * 2020-04-22 2021-10-28 中山康方生物医药有限公司 抗cd73的抗体及其用途
CN114380915B (zh) * 2020-10-19 2024-03-22 中山康方生物医药有限公司 抗cd73的抗体及其用途

Similar Documents

Publication Publication Date Title
JP2025506318A5 (enExample)
JP2023504003A5 (enExample)
JP2020019787A5 (enExample)
JP2024509018A5 (enExample)
IL302078A (en) Anti-CCR8 monoclonal antibodies and their uses
JP2021514664A5 (enExample)
IL293241A (en) Bispecific antibody, anti-1-pd, anti-vegfa, pharmaceutical preparation containing it and its use
JP2022515318A5 (enExample)
IL276830B1 (en) Anti-claudin 18.2 antibodies and their uses
JP2020502271A5 (enExample)
JP2020522486A5 (enExample)
JP2021515559A5 (enExample)
RU2009115363A (ru) Антагонисты рецепторов для лечения метастатического рака
JP2020510653A5 (ja) Ceaを標的にする多重特異性結合タンパク質
JP2025507817A5 (enExample)
JP2023546743A5 (enExample)
JP2020522474A5 (enExample)
JP2010535713A5 (enExample)
JP2024538669A5 (enExample)
JP2024534468A5 (enExample)
JP2024515618A5 (enExample)
JP2008508858A5 (enExample)
JP2024536881A5 (enExample)
JP2024542192A5 (enExample)
JP2024504331A5 (enExample)